Breyanzi’s Reimbursement in Japan Matched to Kymriah’s and Yescarta’s
Here is a brief preview of this blast: On Wednesday, May 19, Japan’s Ministry of Health, Labor, and Welfare (MHLW) listed Breyanzi (BMS) in the NHI’s reimbursement price list (publication, Nichiyaku, May 2021). Below, Celltelligence provides thoughts on Breyanzi’s lower price in Japan while discussing the potential impact on pricing for upcoming cell therapies.